Journal: Signal Transduction and Targeted Therapy

Article Title: Nanotherapeutic macrophage reprogramming through immunometabolic and microbial modulation for sepsis treatment

doi: 10.1038/s41392-026-02947-3

Figure Lengend Snippet: RNA sequencing and expression profiling of macrophages during sepsis progression. a Schematic overview of the CLP-induced sepsis model in mice and the workflow for RNA sequencing of PBMCs. Created in BioRender ( https://BioRender.com ). b Heatmap of differentially expressed genes between the Control and CLP groups. c GO enrichment analysis of differentially expressed genes from CLP or control mice. d KEGG enrichment analysis of differentially expressed genes from CLP or control mice. e GSEA plots of the type I interferon-mediated signaling pathway and pyrimidine metabolism pathway gene signatures in CLP group relative to Control with their respective enrichment scores (ES) and false discovery rates (FDR). f Network diagram illustrating the interconnection of enriched pathways and the relationships among their associated genes. g Box plots comparing the expression levels of STING between sepsis patients ( n = 82) and healthy controls ( n = 21), based on analysis of GEO datasets. h Box plots comparing the expression levels of DHODH between sepsis patients ( n = 71) and healthy controls ( n = 22), based on analysis of GEO datasets. i Expression levels and quantification of p-STING, STING and DHODH in BMDMs under control conditions and following stimulation with LPS (1 μg/mL). j Analysis of CD86 and CD206 expression and quantification in STING and DHODH knockdown BMDMs following LPS stimulation. Statistical analysis was performed using an unpaired two-tailed Student’s t-test. Data are presented as mean ± SD

Article Snippet: The following antibodies were used: Anti-Vinculin antibody (ab129002, Abcam), Anti-beta Actin antibody (ab8226, Abcam), STING (D1V5L) Rabbit mAb (50494, CST), DHODH (14877-1-AP, Proteintech), CD206/MRC1(E6T5J)XP Rabbit mAb (24595, CST), CD86 (19589, CST), Phospho-STING (Ser365) (D8F4W) Rabbit mAb (72971, CST), TBK1/NAK (D1B4) Rabbit mAb (3504, CST), Phospho-TBK1/NAK (Ser172) (D52C2) Rabbit mAb (5483, CST), IRF-3 (D83B9) Rabbit mAb (4302, CST), Phospho-IRF-3 (Ser396) (D6O1M) Rabbit mAb (29047, CST), iNOS Rabbit antibody (ab270449, Abcam), Arginase-1 Rabbit mAb (F0421, Selleck), IL-1 beta (12507, CST), Goat Anti-mouse IgG H&L (ab6708, Abcam), Goat Anti-Rabbit IgG H&L (ab205718, Abcam).

Techniques: RNA Sequencing, Expressing, Profiling, Control, Analysis, Knockdown, Two Tailed Test, Significance Assay

Journal: Nature cancer

Article Title: Copper depletion inhibits electron transport chain activity and nucleotide synthesis to boost leukemia therapy

doi: 10.1038/s43018-026-01177-4

Figure Lengend Snippet: (a) Volcano plot of changing metabolites between SLC31A1-KO SEM cells and control cells. n = 3 biological replicates. (b) Aspartate and dihydroorotate (DHO) levels at baseline in SLC31A1-KO or control SEM cells with eGFP or SLC31A1 rescue. (c) Nucleotide levels in SLC31A1-KO SEM cells with eGFP or SLC31A1 rescue. (d) Volcano plot of changing metabolites between day 8 BCS-treated MOLT16 cells and control cells. n = 3 biological replicates. (e-f) Aspartate and (f) nucleotide levels in day 8 BCS-treated MOLT16 cells. (g-h) Volcano plot of significantly changing metabolites between day 14 BCS-treated (g) or SLC31A1-KO (h) SEM cells, with amino acids highlighted in pink. n = 3 biological replicates. (i) Western blot for DHODH levels in BCS-treated SEM (day 8), NALM6 (day 6) and MOLT16 cells (day 8); each lane represents an independent biological replicate. Actin is a loading control. . (j) Nucleotide levels in AOX-overexpressing SEM cells treated with BCS for 8 days. (k-l) Levels of aspartate, DHO, and IMP in (k) 14-day BCS-treated SEM cells overexpressing RFP or AOX, (l) or SLC31A1-KO SEM cells overexpressing RFP or AOX. DHO = dihydroorotate, CAA = carbamoyl aspartic acid, AOX = alternative oxidase, IMP = inosine monophosphate. Plotted data are mean ± SD. p-values from Šídák's multiple comparisons test.

Article Snippet: Immunoblotting was performed using the following primary antibodies: For reducing and denaturing western blot: vinculin (CST 13901; 1:2500) Beta actin (CST 8457; 1:2000) GAPDH (CST 2118L; 1:2000) MT-CO1/COX1 (abcam ab14705; 1:2000) COX4I1/COX4 (CST 4850; 1:1000) COX2 (Proteintech 55070–1-AP; 1:5000) DHODH (Santa Cruz E-8 sc-166348; 1:500) SDHA (CST 5839S; 1:1000) SLC31A1 (CST 13086S; 1:500) Beta tubulin (CST 2128P; 1:1000) Human Total OxPhos Cocktail (abcam ab110411; 1:1000) VDAC1/porin (abcam ab154856; 1:1000) Total ERK1/2 (CST 4696S; 1:1000) Phospho-ERK1/2 (CST 4370L; 1:1000) Primary antibodies were diluted in Signal Enhancer HIKARI Solution 1 (Nacalai USA NU00102).

Techniques: Control, Western Blot